argenx SE
XBRU:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
XBRU:ARGX
Watchlist
Price: 598 EUR -1.09%
Market Cap: 35.8B EUR
Have any thoughts about
argenx SE?
Write Note

argenx SE
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

argenx SE
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
argenx SE
XBRU:ARGX
Revenue
$1.9B
CAGR 3-Years
44%
CAGR 5-Years
87%
CAGR 10-Years
126%
Pharming Group NV
AEX:PHARM
Revenue
$285.7m
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
51%
ProQR Therapeutics NV
NASDAQ:PRQR
Revenue
€21.3m
CAGR 3-Years
113%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Revenue
$28.6m
CAGR 3-Years
-61%
CAGR 5-Years
36%
CAGR 10-Years
18%
Merus NV
NASDAQ:MRUS
Revenue
$35.9m
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Revenue
$6.8m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

argenx SE
Revenue Breakdown

Breakdown by Geography
argenx SE

Total Revenue: 1.2B USD
100%
United States: 1B USD
85.3%
EMEA: 72.9m USD
5.9%
Japan: 56.4m USD
4.6%
China: 14.9m USD
1.2%
Show More
Show Less

Breakdown by Segments
argenx SE

Not Available

argenx SE
Glance View

Market Cap
35.8B EUR
Industry
Biotechnology

In a landscape where biotechnology companies tirelessly strive to transform scientific insight into therapeutic breakthroughs, argenx SE stands out with its innovative approach to harnessing the body's own immune system to address severe autoimmune diseases. Originating from the biopharmaceutical hubs of Belgium and the Netherlands, argenx was founded in 2008 and has since positioned itself at the forefront of immunology. At the heart of argenx's operations lies its proprietary SIMPLE Antibody™ technology platform, which engineers differentiated therapeutic antibodies. Guided by a deep understanding of disease biology, the company partners closely with academic institutions and leading pharmaceutical companies to transform promising research insights into viable drug candidates. The company's financial sustenance is woven into its intricate business model, which revolves around the development and commercialization of therapeutic antibodies. Their flagship product, efgartigimod, has made significant strides in treating autoimmune diseases such as generalized myasthenia gravis, showcasing the company's ability to translate its scientific endeavors into substantial revenue streams. Argenx generates income primarily through product sales, milestone payments, and royalties from collaborative partnerships. As the company continues to advance its pipeline and expand its global presence, it demonstrates a robust commitment to addressing unmet medical needs while maintaining a keen eye on sustainable growth and profitability. This delicate balance of innovation and financial acumen allows argenx to reinforce its position in the competitive biotech industry.

ARGX Intrinsic Value
643.62 EUR
Undervaluation 7%
Intrinsic Value
Price

See Also

What is argenx SE's Revenue?
Revenue
1.9B USD

Based on the financial report for Jun 30, 2024, argenx SE's Revenue amounts to 1.9B USD.

What is argenx SE's Revenue growth rate?
Revenue CAGR 10Y
126%

Over the last year, the Revenue growth was 68%. The average annual Revenue growth rates for argenx SE have been 44% over the past three years , 87% over the past five years , and 126% over the past ten years .

Back to Top